Valuation: Guided Therapeutics Inc

Market Cap 2.41Cr 2.07Cr 1.93Cr 1.77Cr 3.34Cr 231.09Cr 3.37Cr 23Cr 8.9Cr 116.04Cr 9.06Cr 8.87Cr 383.94Cr P/E 2024
-3x
P/E 2025 -12.7x
Enterprise Value 2.7Cr 2.31Cr 2.17Cr 1.98Cr 3.74Cr 258.63Cr 3.78Cr 26Cr 9.96Cr 129.87Cr 10Cr 9.92Cr 429.69Cr EV / Sales 2024
1,649x
EV / Sales 2025 64.4x
Free-Float
63.48%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 70 06/03/2023
Chief Tech/Sci/R&D Officer 70 02/12/2010
Director TitleAgeSince
Director/Board Member 70 01/12/2016
Director/Board Member 76 10/04/2006
Chairman 67 01/10/2013
Change 5-day change 1-year change 3-year change Capi.($)
-0.30%+6.47%+27.80%+15.80% 23TCr
+0.24%+7.98%+3.75%-15.66% 15TCr
-0.73%-5.31%-20.93%+24.48% 13TCr
+0.84%-2.56%-53.21%-3.11% 7.1TCr
-1.75%+0.58%-16.51%-12.63% 5.25TCr
-0.31%-1.25%+11.11%+17.95% 5.22TCr
+0.73%+3.81%+29.33%+28.76% 4.33TCr
+0.17%+2.56%+37.65%+50.53% 4.04TCr
-0.59%+1.31%-1.35%+7.28% 3.35TCr
Average -0.19%+1.82%+1.96%+12.60% 8.98TCr
Weighted average by Cap. -0.19%+2.78%+3.64%+10.04%

Financials

2024 2025
Net sales 7T 6T 5.61T 5.13T 9.68T 7L 9.79T 66.41T 25.82T 3L 26.28T 25.71T 11.14L 8L 7L 6L 6L 10.61L 7.34Cr 10.72L 72.76L 28.29L 3.69Cr 28.8L 28.17L 12Cr
Net income -24.17L -20.71L -19.38L -17.72L -33.43L -23Cr -33.79L -2.29Cr -89.16L -12Cr -90.75L -88.79L -38Cr -31.96L -27.39L -25.62L -23.43L -44.21L -31Cr -44.68L -3.03Cr -1.18Cr -15Cr -1.2Cr -1.17Cr -51Cr
Net Debt 17.71L 15.18L 14.2L 12.98L 24.5L 17Cr 24.76L 1.68Cr 65.33L 8.52Cr 66.5L 65.06L 28Cr 28.76L 24.65L 23.06L 21.08L 39.78L 28Cr 40.2L 2.73Cr 1.06Cr 14Cr 1.08Cr 1.06Cr 46Cr
Logo Guided Therapeutics Inc
Guided Therapeutics, Inc. is a medical technology company. The Company is focused on developing medical devices that have the potential to improve healthcare. The Company’s primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.
Employees
-